Assertio Holdings, Inc. (ASRT)
USD 0.62
(2.78%)
USD 0.62
(2.78%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 152.06 Million USD | -2.67% |
| 2022 | 156.23 Million USD | 40.73% |
| 2021 | 111.01 Million USD | 4.46% |
| 2020 | 106.27 Million USD | -53.69% |
| 2019 | 229.5 Million USD | -26.39% |
| 2018 | 311.77 Million USD | -18.11% |
| 2017 | 380.72 Million USD | -16.49% |
| 2016 | 455.89 Million USD | 33.02% |
| 2015 | 342.73 Million USD | -12.2% |
| 2014 | 390.36 Million USD | 190.87% |
| 2013 | 134.2 Million USD | 47.78% |
| 2012 | 90.81 Million USD | -31.7% |
| 2011 | 132.97 Million USD | 64.64% |
| 2010 | 80.76 Million USD | 39.9% |
| 2009 | 57.72 Million USD | 65.69% |
| 2008 | 34.84 Million USD | -46.87% |
| 2007 | 65.58 Million USD | 586.63% |
| 2006 | 9.55 Million USD | 116.81% |
| 2005 | 4.4 Million USD | 2074.73% |
| 2004 | 202.56 Thousand USD | -79.37% |
| 2003 | 981.99 Thousand USD | -40.89% |
| 2002 | 1.66 Million USD | -54.78% |
| 2001 | 3.67 Million USD | 106.81% |
| 2000 | 1.77 Million USD | 1440.16% |
| 1999 | 115.32 Thousand USD | -85.58% |
| 1998 | 800 Thousand USD | 33.33% |
| 1997 | 600 Thousand USD | 100.0% |
| 1996 | 300 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 32.44 Million USD | -1.63% |
| 2024 Q2 | 31.12 Million USD | -4.07% |
| 2023 FY | 152.06 Million USD | -2.67% |
| 2023 Q2 | 40.99 Million USD | -3.47% |
| 2023 Q3 | 35.62 Million USD | -13.09% |
| 2023 Q4 | 32.98 Million USD | -7.42% |
| 2023 Q1 | 42.46 Million USD | -15.66% |
| 2022 FY | 156.23 Million USD | 40.73% |
| 2022 Q4 | 50.35 Million USD | 47.18% |
| 2022 Q1 | 36.53 Million USD | 9.62% |
| 2022 Q2 | 35.13 Million USD | -3.85% |
| 2022 Q3 | 34.21 Million USD | -2.62% |
| 2021 Q2 | 25.37 Million USD | -5.46% |
| 2021 Q3 | 25.47 Million USD | 0.39% |
| 2021 Q4 | 33.33 Million USD | 30.85% |
| 2021 FY | 111.01 Million USD | 4.46% |
| 2021 Q1 | 26.83 Million USD | -11.06% |
| 2020 Q2 | 20.61 Million USD | -1.43% |
| 2020 Q3 | 34.56 Million USD | 67.65% |
| 2020 FY | 106.27 Million USD | -53.69% |
| 2020 Q1 | 20.91 Million USD | -64.68% |
| 2020 Q4 | 30.17 Million USD | -12.7% |
| 2019 Q4 | 59.22 Million USD | 7.4% |
| 2019 Q2 | 57.2 Million USD | -1.25% |
| 2019 Q3 | 55.14 Million USD | -3.59% |
| 2019 FY | 229.5 Million USD | -26.39% |
| 2019 Q1 | 57.92 Million USD | 35.99% |
| 2018 Q3 | 77.49 Million USD | 22.47% |
| 2018 FY | 311.77 Million USD | -18.11% |
| 2018 Q1 | 128.4 Million USD | 36.01% |
| 2018 Q2 | 63.27 Million USD | -50.72% |
| 2018 Q4 | 42.59 Million USD | -45.03% |
| 2017 Q4 | 94.4 Million USD | -1.05% |
| 2017 FY | 380.72 Million USD | -16.49% |
| 2017 Q1 | 90.44 Million USD | -27.01% |
| 2017 Q2 | 100.45 Million USD | 11.07% |
| 2017 Q3 | 95.41 Million USD | -5.02% |
| 2016 FY | 455.89 Million USD | 33.02% |
| 2016 Q4 | 123.91 Million USD | 12.11% |
| 2016 Q3 | 110.52 Million USD | -5.28% |
| 2016 Q2 | 116.68 Million USD | 11.36% |
| 2016 Q1 | 104.78 Million USD | -5.75% |
| 2015 Q2 | 94.5 Million USD | 193.46% |
| 2015 Q1 | 32.2 Million USD | -83.45% |
| 2015 Q3 | 104.85 Million USD | 10.95% |
| 2015 Q4 | 111.17 Million USD | 6.02% |
| 2015 FY | 342.73 Million USD | -12.2% |
| 2014 FY | 390.36 Million USD | 190.87% |
| 2014 Q4 | 194.6 Million USD | 277.98% |
| 2014 Q3 | 51.48 Million USD | -23.99% |
| 2014 Q2 | 67.73 Million USD | -11.51% |
| 2014 Q1 | 76.54 Million USD | 88.49% |
| 2013 FY | 134.2 Million USD | 47.78% |
| 2013 Q1 | 26.17 Million USD | -1.56% |
| 2013 Q3 | 37.46 Million USD | 25.02% |
| 2013 Q2 | 29.96 Million USD | 14.48% |
| 2013 Q4 | 40.6 Million USD | 8.41% |
| 2012 Q3 | 33.28 Million USD | 135.88% |
| 2012 Q1 | 16.83 Million USD | 38.77% |
| 2012 FY | 90.81 Million USD | -31.7% |
| 2012 Q4 | 26.59 Million USD | -20.11% |
| 2012 Q2 | 14.11 Million USD | -16.19% |
| 2011 Q1 | 83.1 Million USD | 298.39% |
| 2011 Q2 | 21.21 Million USD | -74.47% |
| 2011 Q4 | 12.13 Million USD | -26.57% |
| 2011 FY | 132.97 Million USD | 64.64% |
| 2011 Q3 | 16.52 Million USD | -22.13% |
| 2010 Q3 | 20.12 Million USD | -17.58% |
| 2010 Q1 | 15.36 Million USD | 16.06% |
| 2010 Q2 | 24.41 Million USD | 58.98% |
| 2010 Q4 | 20.85 Million USD | 3.64% |
| 2010 FY | 80.76 Million USD | 39.9% |
| 2009 FY | 57.72 Million USD | 65.69% |
| 2009 Q1 | 9.87 Million USD | 13.28% |
| 2009 Q2 | 11.6 Million USD | 17.59% |
| 2009 Q3 | 23.01 Million USD | 98.26% |
| 2009 Q4 | 13.23 Million USD | -42.5% |
| 2008 Q4 | 8.71 Million USD | -38.24% |
| 2008 Q3 | 14.11 Million USD | 123.45% |
| 2008 Q2 | 6.31 Million USD | 10.77% |
| 2008 Q1 | 5.7 Million USD | 7.87% |
| 2008 FY | 34.84 Million USD | -46.87% |
| 2007 Q4 | 5.28 Million USD | -90.0% |
| 2007 Q1 | 3.82 Million USD | -23.98% |
| 2007 FY | 65.58 Million USD | 586.63% |
| 2007 Q2 | 3.6 Million USD | -5.77% |
| 2007 Q3 | 52.86 Million USD | 1365.08% |
| 2006 FY | 9.55 Million USD | 116.81% |
| 2006 Q3 | 958.78 Thousand USD | -56.68% |
| 2006 Q2 | 2.21 Million USD | 64.91% |
| 2006 Q1 | 1.34 Million USD | -57.57% |
| 2006 Q4 | 5.03 Million USD | 425.34% |
| 2005 FY | 4.4 Million USD | 2074.73% |
| 2005 Q1 | 18.75 Thousand USD | 0.0% |
| 2005 Q2 | 428.46 Thousand USD | 2185.16% |
| 2005 Q3 | 795.03 Thousand USD | 85.55% |
| 2005 Q4 | 3.16 Million USD | 297.86% |
| 2004 Q4 | 18.75 Thousand USD | -70.75% |
| 2004 Q1 | 119.72 Thousand USD | 7.08% |
| 2004 FY | 202.56 Thousand USD | -79.37% |
| 2004 Q2 | - USD | -100.0% |
| 2004 Q3 | 64.09 Thousand USD | 0.0% |
| 2003 Q3 | 364.55 Thousand USD | 207.27% |
| 2003 Q4 | 111.81 Thousand USD | -69.33% |
| 2003 Q2 | 118.64 Thousand USD | -69.34% |
| 2003 Q1 | 386.98 Thousand USD | 33.92% |
| 2003 FY | 981.99 Thousand USD | -40.89% |
| 2002 Q4 | 288.97 Thousand USD | 106.52% |
| 2002 FY | 1.66 Million USD | -54.78% |
| 2002 Q3 | 139.92 Thousand USD | -77.08% |
| 2002 Q2 | 610.56 Thousand USD | -1.79% |
| 2002 Q1 | 621.71 Thousand USD | -37.15% |
| 2001 Q3 | 1.2 Million USD | -85.49% |
| 2001 Q1 | 637.42 Thousand USD | 47.44% |
| 2001 FY | 3.67 Million USD | 106.81% |
| 2001 Q2 | 8.32 Million USD | 1206.51% |
| 2001 Q4 | 989.28 Thousand USD | -18.15% |
| 2000 FY | 1.77 Million USD | 1440.16% |
| 2000 Q4 | 432.31 Thousand USD | 13.19% |
| 2000 Q3 | 381.92 Thousand USD | -34.78% |
| 2000 Q1 | 376.41 Thousand USD | 2355.91% |
| 2000 Q2 | 585.56 Thousand USD | 55.56% |
| 1999 FY | 115.32 Thousand USD | -85.58% |
| 1999 Q4 | 15.32 Thousand USD | -84.67% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1999 Q1 | 100 Thousand USD | -66.67% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1998 FY | 800 Thousand USD | 33.33% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 200 Thousand USD | 100.0% |
| 1998 Q4 | 300 Thousand USD | 50.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | -50.0% |
| 1997 Q2 | 200 Thousand USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| 1997 FY | 600 Thousand USD | 100.0% |
| 1997 Q1 | 200 Thousand USD | 0.0% |
| 1996 FY | 300 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 67.253% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | -66.316% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 73.169% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 68.763% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -200.633% |
| Journey Medical Corporation | 79.18 Million USD | -92.052% |
| Dynavax Technologies Corporation | 232.28 Million USD | 34.533% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -30.718% |
| Bright Green Corporation | 401.49 Thousand USD | -37776.067% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 77.471% |
| Embecta Corp. | 1.12 Billion USD | 86.432% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -531.181% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -531.181% |
| SCYNEXIS, Inc. | 140.14 Million USD | -8.511% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2511.798% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1197.281% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -7785.364% |
| Alpha Teknova, Inc. | 36.68 Million USD | -314.538% |
| Safety Shot Inc | 202.67 Thousand USD | -74932.812% |
| Procaps Group, S.A. | 409.92 Million USD | 62.903% |
| Cosmos Health Inc. | 53.37 Million USD | -184.897% |
| Theratechnologies Inc. | 81.76 Million USD | -85.985% |
| Harrow Health, Inc. | 130.19 Million USD | -16.803% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -1094.103% |
| Biofrontera Inc. | 34.07 Million USD | -346.33% |
| DURECT Corporation | 8.54 Million USD | -1679.001% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 74.969% |
| Cronos Group Inc. | 88.84 Million USD | -71.17% |
| OptiNose, Inc. | 70.98 Million USD | -114.221% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 65.652% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -2234.791% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 64.891% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -1141.527% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -284.474% |
| Radius Health, Inc. | 2.88 Billion USD | 94.724% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -370.675% |
| ProPhase Labs, Inc. | 44.38 Million USD | -242.621% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 85.057% |
| Procaps Group S.A. | 409.92 Million USD | 62.903% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -11579.647% |
| Viatris Inc. | 15.42 Billion USD | 99.014% |
| Rockwell Medical, Inc. | 83.61 Million USD | -81.875% |
| Aytu BioPharma, Inc. | 81 Million USD | -87.735% |
| SIGA Technologies, Inc. | 139.91 Million USD | -8.685% |
| Tilray Brands, Inc. | 788.94 Million USD | 80.725% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -18.562% |
| Shineco, Inc. | 9.8 Million USD | -1451.431% |
| PetIQ, Inc. | 1.1 Billion USD | 86.2% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -1267141.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 91.942% |
| Alimera Sciences, Inc. | 80.75 Million USD | -88.311% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -773.107% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -14027.489% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -443.822% |
| Hempacco Co., Inc. | 4.04 Million USD | -3658.839% |
| Talphera, Inc. | 651 Thousand USD | -23259.293% |
| Alvotech | 91.43 Million USD | -66.316% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 51.97% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 88.27% |
| Currenc Group, Inc. | 53.25 Million USD | -185.547% |
| Kamada Ltd. | 144.75 Million USD | -5.05% |
| Indivior PLC | 1.09 Billion USD | 86.087% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2835.338% |
| Flora Growth Corp. | 76.07 Million USD | -99.904% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -14027.489% |
| Evolus, Inc. | 202.08 Million USD | 24.75% |
| HUTCHMED (China) Limited | 837.99 Million USD | 81.853% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 76.401% |
| Akanda Corp. | 2.16 Million USD | -6940.062% |